Devyser has been awarded a tender from Héma-Québec, in Québec, Canada, for its non-invasive fetal RHD detection product, used to determine fetal RHD status from maternal plasma in early pregnancy. The tender is initially valid over three years starting in 2023, with a potential extension of two additional years. The total possible order value amounts to just over 16 MSEK.

National and regional screening programs represent an important upside for us, and this award is a true confirmation of our products competitiveness in these large international tenders. Devyser has submitted a regulatory registration application of the RHD product in Canada as part of the tender process. The company already holds an MDSAP certification since 2020, which is a requirement for registration of products in Canada.

The award is subject to a testing period for verification and validation during the first half of 2023 and the first order from the tender is expected around mid-2023 once the final award contract is in place.